Artimplant invests in expanded sales of its own product instead of via sale channelsTuesday, 03 January 2012
Biomaterials Company, Artimplant which focuses on solutions to problems in orthopedic and oral surgery reports that with effect from January 1, 2012, it will take over responsibility for sales of Artelon® CMC Spacer, previously handled by the licensee SBi.
AdvertisementSince December 2011, Artimplant has had a stronger sales organization in place in the USA, which it is felt will contribute positively to the company's presence and sales volumes, saod the company in a press release. By assuming responsibility for sales of Artelon® CMC Spacer and other products for restoring joint surfaces, Artimplant will have a more complete product offering on the US market. Artelon® CMC Spacer is considered to have major market potential, which Artimplant is in a better position to develop by assuming direct control of sales.
The former licensee, SBI, will cease sales of Artimplant products for restoring joint surfaces in conjunction with Artimplant taking back the sales rights for these products.
This is an integral part of Artimplant's focus on reinforcing its presence on the very important US market.
By Scancomark.se Team
What do you think about the above article? Please leave us a comment and reaction. Thank you.TeliaSonera's credit rating is in danger